PEG-rhG-CSF预防小细胞肺癌化疗后中性粒细胞减少症的效果分析  

Effect Analysis of PEG-rhG-CSF in Preventing Neutropenia of Small Cell Lung Cancer after Chemotherapy

作　　者：刘社清 宋现书 陈华强 LIU Sheqing;SONG Xianshu;CHEN Huaqiang(Department of ComprehensiveⅢ,Beijing Chaoyang Huanxing Cancer Hospital,Beijing 100040,China;不详)

机构地区：[1]北京市朝阳区桓兴肿瘤医院综合三科,北京100040

出　　处：《中国医学创新》2024年第23期15-18,共4页Medical Innovation of China

摘　　要：目的:探讨聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)预防小细胞肺癌化疗后中性粒细胞减少症的效果。方法:选取2020年1月—2023年3月北京市朝阳区桓兴肿瘤医院收治的小细胞肺癌化疗患者200例,按照信封法分为两组。对照组(n=98)化疗后应用重组人粒细胞刺激因子(rhGCSF),观察组(n=102)化疗后应用PEG-rhG-CSF。比较两组中性粒细胞减少症发生率、免疫功能、血清肿瘤标志物水平及不良反应发生情况。结果:观察组中性粒细胞减少症发生率低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)水平均高于对照组,CD8^(+)及细胞角质蛋白19片段(Cyfra21-1)、胃泌素释放肽前体(Pro-GRP)、神经元特异性烯醇化酶(NSE)水平均低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:小细胞肺癌化疗后应用PEG-rhG-CSF能有效预防中性粒细胞减少症的发生,改善机体免疫功能,抑制血清肿瘤标志物水平,且安全性良好。Objective:To investigate the effect of PEGylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF)in preventing neutropenia of small cell lung cancer after chemotherapy.Method:A total of 200 patients with small cell lung cancer treated with chemotherapy in Beijing Chaoyang Huanxing Cancer Hospital from January 2020 to March 2023 were selected and divided into two groups according to envelope method.The control group(n=98)was treated with Recombinant Human Granulocyte Colony-stimulating Factor(rhG-CSF)after chemotherapy,and the observation group(n=102)was treated with PEG-rhG-CSF after chemotherapy.The incidence of neutropenia,immune function,serum tumor markers and the occurrence of adverse reactions were compared between the two groups.Result:The incidence of neutropenia in observation group was lower than that in control group,the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+) and CD4^(+) in the observation group were higher than those in the control group,and the levels of CD8^(+),cyto-keratin 19 fragment(Cyfra21-1),pro-gastrin-releasing peptide(Pro-GRP)and neuron specific enolase(NSE)were lower than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application of PEG-rhG-CSF after chemotherapy for small cell lung cancer can effectively prevent the occurrence of neutropenia,improve the immune function of the body,inhibit the levels of serum tumor markers,and has good safety.

关 键 词：小细胞肺癌 化疗 聚乙二醇化重组人粒细胞刺激因子 中性粒细胞减少症 

分 类 号：R734.2[医药卫生—肿瘤]